Literature DB >> 26622587

Therapeutic effect of lymphokine-activated killer cells treated with low-dose ionizing radiation on osteosarcoma.

Lei Zhao1, Ming Lv2, Wuliya Sayimu3, Wei Liu4, Huawu Zhang1, B O Jiang1, Dong Wang1.   

Abstract

The aim of the present study was to investigate the effect of lymphokine-activated killer (LAK) cells, which received low-dose ionizing radiation, on the treatment of osteosarcoma in rats. The cultured UMR-106 cells were inoculated under the anterior chest skin of 24 rats to establish an osteosarcoma model. In addition, the LAK cells from 24 mice were exposed to doses of 0 (control group), 0.65 or 3.25 mGy X-ray radiation. The tritiated thymidine (3H-TdR) release method and Winn assay were performed to determine the antitumor effects of the LAK cells. The proliferation of the mouse LAK cells treated with 3.25 mGy radiation was significantly higher than that for those treated with 0 or 0.65 mGy radiation, which suggested that low-dose ionizing radiation stimulates the proliferation of LAK cells. The tumor-bearing rats were divided into three groups and injected with LAK cells that had already received 0, 0.65 or 3.25 mGy radiation. The mean survival time of the 3.25-mGy group was longer than that of the 0- and 0.65-mGy groups. After 30 days, tumors with weights of ~6.25 and 2.0 g were identified in the rats of the 0- and 0.65-mGy groups, respectively. However, tumor proliferation was not detectable in the rats of the 3.25-mGy radiation group. Therefore, low-dose ionizing radiation effectively kills osteosarcoma cells in rats by stimulating the proliferation and enhancing the cytotoxicity of LAK cells.

Entities:  

Keywords:  antitumor; low-dose ionizing; lymphokine-activated killer cells; osteosarcoma; proliferation

Year:  2015        PMID: 26622587      PMCID: PMC4509114          DOI: 10.3892/ol.2015.3271

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  23 in total

1.  Cancer stem cells: seeds of growth in osteosarcoma.

Authors:  Jennifer Gillette; Sheila Nielsen-Preiss
Journal:  Cancer Biol Ther       Date:  2009-03-15       Impact factor: 4.742

2.  Clinical experience with In-111 labeled LAK cells and TILS for tumor localization.

Authors:  K Uno; M Tsukuda; K Kushida; Y Ono; S Yanoma; T Ono; M Saito; N Arimizu
Journal:  Prog Clin Biol Res       Date:  1990

3.  Radiation-induced Extra-osseous Osteosarcoma-A Case Report and Review of Literature.

Authors:  Syam Vikram; Surij Salih; Aswathy Krishnan; M P Nizamudheen; Sajith Babu; Sithara Aravind; N Sangeetha; B Sateesan
Journal:  Indian J Surg Oncol       Date:  2013-08-28

Review 4.  Primary bone osteosarcoma in the pediatric age: state of the art.

Authors:  Alessandra Longhi; Costantino Errani; Massimiliano De Paolis; Mario Mercuri; Gaetano Bacci
Journal:  Cancer Treat Rev       Date:  2006-07-24       Impact factor: 12.111

5.  Stable interference of EWS-FLI1 in an Ewing sarcoma cell line impairs IGF-1/IGF-1R signalling and reveals TOPK as a new target.

Authors:  D Herrero-Martín; D Osuna; J L Ordóñez; V Sevillano; A S Martins; C Mackintosh; M Campos; J Madoz-Gúrpide; A P Otero-Motta; G Caballero; A T Amaral; D H Wai; Y Braun; M Eisenacher; K-L Schaefer; C Poremba; E de Alava
Journal:  Br J Cancer       Date:  2009-06-02       Impact factor: 7.640

6.  Outcomes after limb sparing resection in primary malignant pelvic tumors.

Authors:  A Puri; M Pruthi; A Gulia
Journal:  Eur J Surg Oncol       Date:  2013-11-05       Impact factor: 4.424

7.  Intratumoral LAK cell and interleukin-2 therapy of human gliomas.

Authors:  D Barba; S C Saris; C Holder; S A Rosenberg; E H Oldfield
Journal:  J Neurosurg       Date:  1989-02       Impact factor: 5.115

8.  Targeting the osteosarcoma cancer stem cell.

Authors:  Valerie A Siclari; Ling Qin
Journal:  J Orthop Surg Res       Date:  2010-10-27       Impact factor: 2.359

9.  Immunomodulation in a treatment program including pre- and post-operative interleukin-2 and chemotherapy for childhood osteosarcoma.

Authors:  Roberto Luksch; Daniela Perotti; Graziella Cefalo; Carlo Gambacorti Passerini; Maura Massimino; Filippo Spreafico; Michela Casanova; Andrea Ferrari; Monica Terenziani; Daniela Polastri; Felicita Gambirasio; Marta Podda; Fabio Bozzi; Fabrizio Ravagnani; Giorgio Parmiani; Franca Fossati Bellani
Journal:  Tumori       Date:  2003 May-Jun

10.  Elotuzumab enhances natural killer cell activation and myeloma cell killing through interleukin-2 and TNF-α pathways.

Authors:  Balaji Balasa; Rui Yun; Nicole A Belmar; Melvin Fox; Debra T Chao; Michael D Robbins; Gary C Starling; Audie G Rice
Journal:  Cancer Immunol Immunother       Date:  2014-10-07       Impact factor: 6.968

View more
  3 in total

1.  Influence of different ex vivo cell culture methods on the proliferation and anti-tumor activity of cytokine-induced killer cells from gastric cancer patients.

Authors:  Bin Shi; Aixia Sun; Xiaorui Zhang
Journal:  Onco Targets Ther       Date:  2018-05-08       Impact factor: 4.147

2.  Efficacy and safety of cord blood-derived dendritic cells plus cytokine-induced killer cells combined with chemotherapy in the treatment of patients with advanced gastric cancer: a randomized Phase II study.

Authors:  Ying Mu; Wei-Hua Wang; Jia-Ping Xie; Ying-Xin Zhang; Ya-Pei Yang; Chang-Hui Zhou
Journal:  Onco Targets Ther       Date:  2016-07-25       Impact factor: 4.147

Review 3.  Hedgehog signalling in the tumourigenesis and metastasis of osteosarcoma, and its potential value in the clinical therapy of osteosarcoma.

Authors:  Zhihong Yao; Lei Han; Yongbin Chen; Fei He; Bin Sun; Santosh Kamar; Ya Zhang; Yihao Yang; Cao Wang; Zuozhang Yang
Journal:  Cell Death Dis       Date:  2018-06-13       Impact factor: 8.469

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.